Nucleic Acids Research, 2001, Vol. 29, No. 8 1661-1671
© 2001 Oxford University Press
PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells
1Department of Urology, 2Department of Pathology and 3Department of Neurosurgery, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA and 4Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
Transformation of normal cloned rat embryo fibroblast (CREF) cells with cellular oncogenes results in acquisition of anchorage-independent growth and oncogenic potential in nude mice. These cellular changes correlate with an induction in the expression of a cancer progression-promoting gene, progression elevated gene-3 (PEG-3). To define the mechanism of activation of PEG-3 as a function of transformation by the Ha-ras and v-raf oncogenes, evaluations of the signaling and transcriptional regulation of the ~2.0 kb promoter region of the PEG-3 gene, PEG-Prom, was undertaken. The full-length and various mutated regions of the PEG-Prom were linked to a luciferase reporter construct and tested for promoter activity in CREF and oncogene-transformed CREF cells. An analysis was also performed using CREF cells doubly transformed with Ha-ras and the Ha-ras specific suppressor gene Krev-1, which inhibits the transformed phenotype in vitro. These assays document an association between expression of the transcription regulator PEA3 and PEG-3. The levels of PEA3 and PEG-3 RNA and proteins are elevated in the oncogenically transformed CREF cells, and reduced in transformation and tumorigenic suppressed Ha-ras/Krev-1 doubly transformed CREF cells. Enhanced tumorigenic behavior, PEG-3 promoter function and PEG-3 expression in Ha-ras transformed cells were all dependent upon increased activity within the mitogen-activated protein kinase (MAPK) pathway. Electrophoretic mobility shift assays and DNase I footprinting experiments indicate that PEA3 binds to sites within the PEG-Prom in transformed rodent cells in an area adjacent to the TATA box in a MAPK-dependent fashion. These findings demonstrate an association between Ha-ras and v-raf transformation of CREF cells with elevated PEA3 and PEG-3 expression, and they implicate MAPK signaling via PEA3 as a signaling cascade involved in activation of the PEG-Prom.
* To whom correspondence should be addressed at: Departments of Pathology and Urology, Columbia University, College of Physicians and Surgeons, BB-1501, 630 West 168th Street, New York, NY 10032, USA. Tel: +1 212 305 3441; Fax: +1 212 305 8177; Email: pbf1{at}columbia.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Hua, B. Chen, M. Bai, H. Yu, X. Wu, and W. Jin PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells Acta Biochim Biophys Sin, January 1, 2009; 41(1): 63 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-z. Su, S.-G. Lee, L. Emdad, I. V. Lebdeva, P. Gupta, K. Valerie, D. Sarkar, and P. B. Fisher Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN) PNAS, December 30, 2008; 105(52): 20906 - 20911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-G. Lee, Z.-Z. Su, L. Emdad, D. Sarkar, and P. B. Fisher Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc PNAS, November 14, 2006; 103(46): 17390 - 17395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Fisher Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Res., November 15, 2005; 65(22): 10128 - 10138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sarkar, Z.-z. Su, N. Vozhilla, E. S. Park, A. Randolph, K. Valerie, and P. B. Fisher Targeted Virus Replication Plus Immunotherapy Eradicates Primary and Distant Pancreatic Tumors in Nude Mice Cancer Res., October 1, 2005; 65(19): 9056 - 9063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sarkar, Z.-z. Su, N. Vozhilla, E. S. Park, P. Gupta, and P. B. Fisher Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice PNAS, September 27, 2005; 102(39): 14034 - 14039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Z. Su, D. Sarkar, L. Emdad, G. J. Duigou, C. S. H. Young, J. Ware, A. Randolph, K. Valerie, and P. B. Fisher Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter PNAS, January 25, 2005; 102(4): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-z. Su, M. Leszczyniecka, D.-c. Kang, D. Sarkar, W. Chao, D. J. Volsky, and P. B. Fisher Insights into glutamate transport regulation in human astrocytes: Cloning of the promoter for excitatory amino acid transporter 2 (EAAT2) PNAS, February 18, 2003; 100(4): 1955 - 1960. [Abstract] [Full Text] [PDF]
|
|